Bryn Pharma Raises $11 Million in Financing to Advance Bi-Dose Epinephrine Nasal Spray for Anaphylaxis
Bryn Pharma Raises $11 Million in Financing to Advance Bi-Dose Epinephrine Nasal Spray for Anaphylaxis
08/04/20, 1:20 PM
Location
raleighMoney raised
$11 million
Industry
healthcare
Bryn Pharma, LLC ("Bryn" or the "Company"), a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced that it has raised an additional $11 million in financing to fund the remaining development and regulatory approval activities, and pre-launch commercialization program for BRYN-NDS1C, its bi-dose epinephrine nasal spray. The financing was an extension of the financing transaction completed by the Company in October 2019 and brings the total proceeds from the transaction to $26 million. This was the fourth financing series completed by the Company. Participants included existing and new investors comprised of investment funds, family offices and private investors.
Company Info
Location
7101 millstone ridge court
raleigh, north carolina, united states
Additional Info
Bryn Pharma is a privately held pharmaceutical company based in North Carolina. Primary focus is on the development and commercialization of innovative allergy products for the management of anaphylaxis.
The mission of Bryn Pharma is to empower patients with a life-saving device that is small enough to comfortably fit in your pocket and easy to use in the event of an anaphylactic attack.
Our intranasal delivery system will be an exciting alternative to epinephrine auto-injectors providing patients a needle-free option that is easy to use, portable, and affordable.